Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Omadacycline - Paratek Pharmaceuticals

Next Previous
X
Search
Drug Profile

Omadacycline - Paratek Pharmaceuticals

Alternative Names: Amadacycline; BAY 73-6944; BAY 73-7388; MK-2764; Neopentyl aminomethylminocycline; NUZYRA; PTK-0796; ZL 2401

Latest Information Update: 20 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tufts University
  • Developer Merck & Co; Paratek Pharmaceuticals; ZAI Lab
  • Class Anti-infectives; Anti-inflammatories; Antibacterials; Small molecules; Tetracyclines
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Nontuberculous mycobacterium infections
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Community-acquired pneumonia; Skin and soft tissue infections
  • Preregistration Anthrax
  • Phase II Cystitis; Nontuberculous mycobacterium infections; Pyelonephritis; Urinary tract infections
  • Phase I Bacterial infections
  • No development reported Acute sinusitis; Plague
  • Discontinued Nosocomial infections

Most Recent Events

  • 16 Apr 2024 Zai Lab initiates a phase I trial (In volunteers) in China (PO) (NCT06462326)
  • 27 Mar 2024 Paratek Pharmaceuticals completes phase IIIb trial for Community-acquired pneumonia in Bulgaria, Croatia, Georgia, Hungary, Poland, Russia, Serbia and Ukraine (IV, PO) (EudraCT2020-002986-32) (NCT04779242)
  • 05 Mar 2024 Preclinical trials in Anthrax in USA (Inhalation) prior to March 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top